Next Generation News and Research

RSS

MorphoSys unveils next-generation antibody technology Ylanthia

MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.

6 Dec 2011

Obesity maybe passed down from fathers to kids: Study

Australian researchers have found that the sperm of overweight fathers appears to carry a molecular signal that causes their offspring to inherit obesity. This may be more severe in female children and males they add.

5 Dec 2011

Researchers uncover binding pocket of 'functional significance' in Ras oncoprotein

A drug discovery team at Genentech, Inc., has uncovered a chink in the molecular armor of Ras, the most commonly occurring oncogene, which is a gene that when mutated has the potential of causing cancer in humans.

5 Dec 2011

American Society of Hematology 2012 Scholar Awards announced

The American Society of Hematology (ASH) announces the recipients of its 2012 Scholar Awards. The ASH Scholar Awards provide monetary support for fellows and junior faculty pursuing research careers to assist them during the critical period in which they must complete their training and achieve status as an independent investigator.

3 Dec 2011

Agilent expands life sciences business with two strategic acquisitions

Agilent Technologies Inc. today announced it is expanding its life sciences business with two strategic acquisitions.

2 Dec 2011

USPTO issues Notice of Allowance to Emboline's aortic devices for TAVR procedures

Emboline, Inc., an emerging medical device company, has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its aortic embolic protection devices for percutaneous heart valve repair and replacement.

1 Dec 2011

New gene therapy approach safe for patients with muscular dystrophy

Researchers at the University of North Carolina at Chapel Hill have shown that it is safe to cut and paste together different viruses in an effort to create the ultimate vehicle for gene therapy. In a phase I clinical trial, the investigators found no side effects from using a "chimeric" virus to deliver replacement genes for an essential muscle protein in patients with muscular dystrophy.

1 Dec 2011

Boston Scientific provides new warranty for ICDs and CRT-Ds

Boston Scientific Corporation announced that, along with today's introduction of a new family of INCEPTA and ENERGEN implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), it is providing an extended warranty for these devices in the U.S. and many international countries of up to 10 years, depending on model.

1 Dec 2011

NovaSom introduces MediTrack OSA management platform

NovaSom, Inc., the leader in obstructive sleep apnea (OSA) home testing and cost-containment solutions, announces the launch of its next generation MediTrack cloud-based CRM application.

1 Dec 2011

Ambry Genetics deploys EMC Isilon scale-out NAS for gene sequencing

EMC Corporation today announced that Ambry Genetics, a leading commercial provider of clinical diagnostic and genomic services, has deployed EMC Isilon scale-out NAS to power its advanced gene sequencing operations, enabling Ambry to advance a range of scientific pursuits while easily managing 100 percent data growth annually.

30 Nov 2011

KI, Mayo Clinic to collaborate on education, research and innovation

Mayo Clinic and the Swedish medical university Karolinska Institutet will sign a long-term agreement to collaborate on education, research and innovation. The two institutions, recognized for leadership in medical research, training and patient care, will pursue joint investigations in regenerative medicine, individualized medicine, metabolism, neurosciences and aging research.

30 Nov 2011

Toshiba introduces Adaptive Iterative Dose Reduction 3D technology at RSNA 2011

To make today's CT examinations even safer, Toshiba America Medical Systems, Inc., unveils next generation dose reduction technology, Adaptive Iterative Dose Reduction 3D, at this year's Radiological Society of North America (RSNA) annual meeting in Chicago.

29 Nov 2011

NIH awards $3.2M for development of highly efficient system of generating nucleic acid molecules

The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.

29 Nov 2011

URMC selects Acuo UCP3 as new vendor neutral archive solution

Acuo Technologies, the leader in high-performance software and services for intelligent medical image lifecycle management and data migration, announced today that University of Rochester Medical Center (URMC) has selected the Universal Clinical Platform (UCP3) as the company's new vendor neutral archive solution.

28 Nov 2011

CHRISTUS Health selects Acuo UCP3 as new vendor neutral archive solution

Acuo Technologies, the leader in high-performance software and services for intelligent medical image lifecycle management and data migration, announced today that CHRISTUS Health has selected the Universal Clinical Platform (UCP3) as the company's new vendor neutral archive solution.

28 Nov 2011

New creative uses of DNA 'barcoding'

The newfound scientific power to quickly "fingerprint" species via DNA is being deployed to unmask quack herbal medicines, reveal types of ancient Arctic life frozen in permafrost, expose what eats what in nature, and halt agricultural and forestry pests at borders, among other applications across a wide array of public interests.

28 Nov 2011

Mass immunization with cervical cancer vaccine switched to a more effective variety

Cervarix is currently offered to girls aged 12 and 13 years to protect against strains of the sexually transmitted human papillomavirus (HPV), which causes most cases of cancer of the cervix, the neck of the womb. Cervarix was picked by the Labour government for the first four-year phase of the NHS programme in 2008 because it offered ‘best overall value’ and more than five million doses have been given.

27 Nov 2011

Ziehm Imaging to highlight Vision RFD hybrid at RSNA 2011

Ziehm Imaging, leading developer, manufacturer and supplier of mobile C-arms, presents its innovative, award-winning product portfolio at RSNA 2011. Latest market analyst reports (GIA[1]) predict substantial growth for the fluoroscopy and mobile C-arm market segments that will be substantially driven by the growing number of minimally invasive procedures.

25 Nov 2011

Cameras in the form of a pill

Cameras ingested in the form of a pill make it possible to examine areas of the stomach and intestines that cannot be reached using traditional equipment. Norwegian researchers are busy developing the next-generation camera pill.

25 Nov 2011

BD MAX MRSA Assay receives CE Mark approval

BD Diagnostics, a segment of BD, today announced that it obtained CE Marking for the BD MAX MRSA Assay to rapidly and accurately identify methicillin-resistant Staphylococcus aureus (MRSA) in patients.

From BD (Becton, Dickinson and Company) 24 Nov 2011